#cardiovascular

A new analysis of a massive amount of global data reached a conclusion similar to that of previous research.

This increased risk is not driven by differences in plaque buildup in the arteries compared with those who are HIV negative.

This connection remained even when researchers took into account various risk factors for cardiovascular disease.

A recent meta-analysis compared side effects linked to Tivicay versus other antiretrovirals.

A recent study found that factors other than coronary plaque likely drive this sex-based difference.

Compared with their HIV-negative peers, HIV-positive individuals have higher rates of treatment for a host of health problems.

A recent study found that the virus was associated with abdominal obesity as well as high triglycerides and low LDL cholesterol.

Aside from taking antiretrovirals, quitting smoking is the number one way people with HIV can lower their risk of illness and death.

The Campbell Foundation awards $100,000 to The Wistar Institute to explore glycobiology and HIV.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Ziagen is included in the combination-tablet regimens Triumeq and Trizivir and the two-drug combo tablet Epzicom.

Additionally, researchers found that those with an unsupressed viral load had higher risk than those people with undetectable HIV.

The condition is a manifestation of cardiovascular disease.

With a grant to follow their large study population through 2021, researchers hope to gain vital new insights about HIV infection.